Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $31 | In Stock | |
5 mg | $71 | In Stock | |
10 mg | $113 | In Stock | |
25 mg | $243 | In Stock | |
50 mg | $388 | In Stock | |
100 mg | $619 | In Stock |
Description | Trofinetide (NNZ-2566) is a synthetic analog of the endogenous N-terminus tripeptide. It has been shown to be neuroprotective in animal models of brain injury. |
In vivo | Trofinetide treatment suppresses IL-1β expression in the injured brain hemisphere for up to 7 days post-PBBI. Trofinetide suppresses penetrating ballistic-like brain injury-induced inflammatory cell infiltration at 3 days following PBBI as compared to vehicle treatment. All doses of Trofinetide completely suppress the delayed occurrence of NCS as compare with the vehicle-treated animals. Trofinetide treatment produces significant reductions in the injury-induced up-regulation of IL-1β, INF-γ, and TNF-α expression. Trofinetide treatment significantly decreases the elevation of IL-6 (79%), E-selectin (81%), IL-1β (76%), and TNF-α (72%) mRNA levels in the injured hemisphere at 12 h post-PBBI, with maximal inhibition occurring between 12 h and 24 h. The high doses of Trofinetide (10 and 100 mg/kg bolus followed by continuous infusion) attenuate non-convulsive seizure (NCS) occurring beyond 2 h after permanent middle cerebral artery occlusion [1][2]. |
Alias | NNZ-2566 |
Molecular Weight | 315.32 |
Formula | C13H21N3O6 |
Cas No. | 853400-76-7 |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | H2O: 44 mg/mL (139.54 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.